{'52WeekChange': -0.67639256,
 'SandP52WeekChange': None,
 'address1': '80 West Lancaster Avenue',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.65,
 'askSize': 2200,
 'averageDailyVolume10Day': 805387,
 'averageVolume': 1856400,
 'averageVolume10days': 805387,
 'beta': 3.087599,
 'beta3Year': None,
 'bid': 3.56,
 'bidSize': 1200,
 'bookValue': 2.808,
 'category': None,
 'circulatingSupply': None,
 'city': 'Devon',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.6573,
 'dayLow': 3.51,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.808,
 'enterpriseToRevenue': None,
 'enterpriseValue': 28689322,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.599571,
 'fiftyTwoWeekHigh': 12.51,
 'fiftyTwoWeekLow': 2.55,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 22831978,
 'forwardEps': -1.52,
 'forwardPE': -2.3486843,
 'fromCurrency': None,
 'fullTimeEmployees': 28,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.12316,
 'heldPercentInstitutions': 0.46945,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/zynerba.com',
 'longBusinessSummary': 'Zynerba Pharmaceuticals, Inc. operates as a clinical '
                        'stage specialty pharmaceutical company. It focuses on '
                        'developing pharmaceutically-produced transdermal '
                        'cannabinoid therapies for rare and near-rare '
                        'neuropsychiatric disorders. The company is developing '
                        'Zygel, a transdermal cannabidiol gel, which is in '
                        'Phase II clinical trial for treating children and '
                        'adolescent patients with developmental and epileptic '
                        'encephalopathies; is in Phase II/III clinical trial '
                        'to treat children and adolescent patients with '
                        'fragile X syndrome; and is in Phase II clinical trial '
                        'for treating children and adolescent patients with '
                        'autism spectrum disorder. It is also developing '
                        'ZYN001, a pro-drug of tetrahydrocannabinol. The '
                        'company was formerly known as AllTranz, Inc. and '
                        'changed its name to Zynerba Pharmaceuticals, Inc. in '
                        'August 2014. Zynerba Pharmaceuticals, Inc. was '
                        'founded in 2007 and is headquartered in Devon, '
                        'Pennsylvania.',
 'longName': 'Zynerba Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 89073640,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_35650772',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -36134396,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.6,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '484-581-7505',
 'previousClose': 3.66,
 'priceHint': 4,
 'priceToBook': 1.2713674,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.6573,
 'regularMarketDayLow': 3.51,
 'regularMarketOpen': 3.6,
 'regularMarketPreviousClose': 3.66,
 'regularMarketPrice': 3.6,
 'regularMarketVolume': 407234,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 24950600,
 'sharesPercentSharesOut': 0.2811,
 'sharesShort': 7012733,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6015013,
 'shortName': 'Zynerba Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.32439998,
 'shortRatio': 2.6,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'ZYNE',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.572,
 'twoHundredDayAverage': 4.521007,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '1bc510aa-0266-36cc-bfa7-1d05f3820a3f',
 'volume': 407234,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.zynerba.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19333'}